| 1. |
Lala A, Hamo CE, Bozkurt B, et al. Standardized definitions for evaluation of acute decompensated heart failure therapies: HF-ARC expert panel paper. JACC Heart Fail, 2024, 12(1): 1-15.
|
| 2. |
Heidenreich PA, Bozkurt B, Aguilar D, et al. 2022 AHA/ACC/HFSA guideline for the management of heart failure: a report of the American College of Cardiology/American Heart Association Joint Committee on clinical practice guidelines. J Am Coll Cardiol, 2022, 79(17): e263-e421.
|
| 3. |
Hanley T, Platts MM. Acetazolamide (diamox) in the treatment of congestive heart-failure. Lancet, 1956, 270(6919): 357-359.
|
| 4. |
Breton S. The cellular physiology of carbonic anhydrases. JOP, 2001, 2(Suppl 4): 159-164.
|
| 5. |
Cooper LB, Mentz RJ, Gallup D, et al. Serum bicarbonate in acute heart failure: relationship to treatment strategies and clinical outcomes. J Card Fail, 2016, 22(9): 738-742.
|
| 6. |
Ellison DH. Clinical pharmacology in diuretic use. Clin J Am Soc Nephrol, 2019, 14(8): 1248-1257.
|
| 7. |
Anderson LE, Henrich WL. Alkalemia-associated morbidity and mortality in medical and surgical patients. South Med J, 1987, 80(6): 729-733.
|
| 8. |
Mazur JE, Devlin JW, Peters MJ, et al. Single versus multiple doses of acetazolamide for metabolic alkalosis in critically ill medical patients: a randomized, double-blind trial. Crit Care Med, 1999, 27(7): 1257-1261.
|
| 9. |
Gheorghiade M, Pang PS. Acute heart failure syndromes. J Am Coll Cardiol, 2009, 53(7): 557-573.
|
| 10. |
Voors AA, Davison BA, Teerlink JR, et al. Diuretic response in patients with acute decompensated heart failure: characteristics and clinical outcome--an analysis from RELAX-AHF. Eur J Heart Fail, 2014, 16(11): 1230-1240.
|
| 11. |
De Bruyne LK. Mechanisms and management of diuretic resistance in congestive heart failure. Postgrad Med J, 2003, 79(931): 268-271.
|
| 12. |
Knauf H, Mutschler E. Sequential nephron blockade breaks resistance to diuretics in edematous states. J Cardiovasc Pharmacol, 1997, 29(3): 367-372.
|
| 13. |
Zahedi K, Barone S, Xu J, et al. Potentiation of the effect of thiazide derivatives by carbonic anhydrase inhibitors: molecular mechanisms and potential clinical implications. PLoS One, 2013, 8(11): e79327.
|
| 14. |
Verbrugge FH, Dupont M, Bertrand PB, et al. Determinants and impact of the natriuretic response to diuretic therapy in heart failure with reduced ejection fraction and volume overload. Acta Cardiol, 2015, 70(3): 265-273.
|
| 15. |
Mullens W, Dauw J, Martens P, et al. Acetazolamide in acute decompensated heart failure with volume overload. N Engl J Med, 2022, 387(13): 1185-1195.
|
| 16. |
Verbrugge FH, Martens P, Ameloot K, et al. Acetazolamide to increase natriuresis in congestive heart failure at high risk for diuretic resistance. Eur J Heart Fail, 2019, 21(11): 1415-1422.
|
| 17. |
Vela Martín P, Matutano Muñoz A, Sánchez Ortiz D, et al. CANDI study: chlorthalidone vs acetazolamide in patients with diuretic resistance in acute heart failure. Rev Esp Cardiol (Engl Ed), 2023, 76(6): 477-480.
|
| 18. |
Kosiorek A, Urban S, Detyna J, et al. Diuretic, natriuretic, and chloride-regaining effects of oral acetazolamide as an add-on therapy for acute heart failure with volume overload: a single-center, prospective, randomized study. Pol Arch Intern Med, 2023, 133(12): 16526.
|
| 19. |
Duta TF, Zulfa PO, Alina M, et al. Efficacy of acetazolamide and loop diuretics combinatorial therapy in congestive heart failure: a meta-analysis. Narra X, 2024, 2(1): e124.
|
| 20. |
Martens P, Dauw J, Verbrugge FH, et al. Decongestion with acetazolamide in acute decompensated heart failure across the spectrum of left ventricular ejection fraction: a prespecified analysis from the ADVOR trial. Circulation, 2023, 147(3): 201-211.
|
| 21. |
Meekers E, Dauw J, Martens P, et al. Renal function and decongestion with acetazolamide in acute decompensated heart failure: the ADVOR trial. Eur Heart J, 2023, 44(37): 3672-3682.
|
| 22. |
Trullàs JC, Peláez AI, Blázquez J, et al. The significance of metabolic alkalosis on acute decompensated heart failure: the ALCALOTIC study. Clin Res Cardiol, 2024, 113(8): 1251-1262.
|
| 23. |
Addison JD, Peterson EJ, Meyenburg L. Intravenous or oral acetazolamide for treatment of diuretic-induced alkalosis in patients with heart failure. Ann Pharmacother, 2023, 57(11): 1241-1247.
|
| 24. |
Martens P, Verbrugge FH, Dauw J, et al. Pre-treatment bicarbonate levels and decongestion by acetazolamide: the ADVOR trial. Eur Heart J, 2023, 44(22): 1995-2005.
|
| 25. |
Bauersachs J. Heart failure drug treatment: the fantastic four. Eur Heart J, 2021, 42(6): 681-683.
|
| 26. |
Mullens W, Schulze PC, Westphal J, et al. Great debate: in patients with decompensated heart failure, acetazolamide in addition to loop diuretics is the first choice. Eur Heart J, 2023, 44(24): 2159-2169.
|
| 27. |
Bueno H, Packer M. Acetazolamide for acute heart failure: is ADVOR a riddle wrapped in a mystery inside an enigma?. Eur Heart J, 2023, 44(37): 3683-3685.
|
| 28. |
国家心血管病中心, 国家心血管病专家委员会心力衰竭专业委员会, 中国医师协会心力衰竭专业委员会, 等. 国家心力衰竭指南 2023(精简版). 中国循环杂志, 2023, 38(12): 1207-1238.
|
